GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » YoY EPS Growth

Revvity (Revvity) YoY EPS Growth : -95.33% (As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Revvity's YoY EPS Growth for the quarter that ended in Mar. 2024 was -95.33%.

Revvity's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.21.


Revvity YoY EPS Growth Historical Data

The historical data trend for Revvity's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity YoY EPS Growth Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.23 218.14 24.50 -44.31 23.33

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.43 -80.28 -88.06 -41.56 -95.33

Revvity YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Revvity's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(5.55-4.5)/ | 4.5 |
=23.33 %

Revvity's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(0.21-4.5)/ | 4.5 |
=-95.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revvity YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Revvity's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121

Revvity (Revvity) Headlines

From GuruFocus

PerkinElmer Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2021 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Revvity Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024